Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the long-term protection against HBV infection in adult subjects, aged 18-40 years vaccinated with three or four doses of Engerix-B 20 to 30 years ago


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02901951
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 4
Start date October 11, 2016
Completion date May 1, 2017

See also
  Status Clinical Trial Phase
Completed NCT03316807 - Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults Phase 4
Completed NCT02991599 - Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients Phase 4
Not yet recruiting NCT03962816 - Immunogenicity and Persistence of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients Phase 4
Not yet recruiting NCT03962881 - Research on Optimal Immunization Strategy of Hepatitis B Vaccine in Chronic Kidney Disease Population Phase 4
Not yet recruiting NCT03962803 - Immunogenicity and Persistence of Hepatitis B Vaccination in HIV-Infected Patients Phase 4
Completed NCT02432430 - Comparison of Immunization Quality Improvement Dissemination Study N/A
Not yet recruiting NCT05099757 - The Immunogenicity and Persistence of Booster Dose With Hepatitis B Vaccine in College Students Phase 4
Completed NCT02963714 - Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients Phase 4
Recruiting NCT01590381 - Assessment of HBV Vaccine Immunity After 18 Years N/A
Completed NCT00519649 - Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination. Phase 4